Abstract

System xc− is a Na+‐independent, Cl−‐dependent transporter which exchanges intracellular glutamate for extracellular cystine across the plasma membrane. Its activity directly regulates the synthesis of the antioxidant glutathione and the extracellular concentration of glutamate in the brain. Dysregulation of the transporter can lead to excessive glutamate release and excitotoxic cell death or the depletion of glutathione stores and the development of oxidative stress. We recently demonstrated that oxidants acutely upregulate System xc− activity by triggering the rapid redistribution of the transporter from intracellular compartments to the cell surface. Our current work suggests that the trafficking of the transporter may be regulated by ubiquitination and that oxidant exposure directly influences the ubiquitination of the transporter. Since increased ubiquitination tends to decrease the cell surface expression of many membrane transporters, we sought to test the hypothesis that System xc− is ubiquitinated and that the ubiquitination status of the transporter regulates both its cell surface expression and activity. We have used a mutagenesis approach to disrupt putative ubiquitination sites and a putative ubiquitin ligase binding site within a myc‐tagged System xc− construct so that we can understand the role ubiquitination plays in regulating the cell surface expression of System xc−. System xc− belongs to the heteromeric amino acid (HAT) transport family, consisting of the transport‐specific light chain subunit xCT and the heavy chain 4f2HC, which associates with numerous light chains in the HAT family. There are seven highly conserved lysine residues within xCT that are located on the cytoplasmic side of the membrane. These residues are located at positions 4, 37, 41, 43, 422, 472, and 473. We have created mutant forms of this construct containing single or multiple lysine to arginine mutations so that we could assess the effect of these mutations on cell surface expression of System xc−. Using biotinylation assays and immunocytochemistry analysis, we have demonstrated that mutation of the N‐terminal lysine residues, but not the C‐terminal residues, increases the cell surface expression of the transporter. In addition, we have identified a GVPAYYLFI domain near the C‐terminus that appears to regulate cell surface expression of xCT. This domain may serve as a u ubiquitin ligase binding or as a tyrosine‐based AP‐2 binding site. We are currently assessing the ubiquitination status of these mutant transporters to determine if ubiquitination regulates cell surface expression of xCT. In addition, we are developing a N‐terminal fluorescence activated peptide (FAP)‐xCT fusion construct that will allow us to rapidly assess xCT cell surface expression. Collectively, these data suggest that System xc− is regulated by changes in its ubiquitination status such that factors which lead to diminished ubiquitination will allow for increased cell surface expression of the transporter.Support or Funding InformationThis work was supported by NSF‐RUI #0848564 and the Biology, Chemistry and Neuroscience Programs at Hope CollegeThis abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call